SCHEMBL10073653

SCHEMBL10073653

CCCC(O)C(C)(C)NS(=O)(=O)c1n[nH]c2ncccc12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3A P49840 1/20 0.35
GSK3B P49841 1/20 0.35
ALDH1A1 P00352 2/20 0.34
KDM4E B2RXH2 1/20 0.34
HPGD P15428 1/20 0.34
HSD17B10 Q99714 1/20 0.34
COMT P21964 1/20 0.33
FTO Q9C0B1 1/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
GLA P06280 1/20 0.32
TSHR P16473 1/20 0.32
MAPT P10636 1/20 0.32
HTT P42858 1/20 0.31
GRM4 Q14833 1/20 0.31
CFTR P13569 1/20 0.31
CNR1 P21554 2/20 0.31
CNR2 P34972 2/20 0.31
MET P08581 1/20 0.30
TRPV1 Q8NER1 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10072893 0.79 ALDH1A1 (0.41) ALDH1A1KDM4EHPGDHSD17B10FTO
SCHEMBL10072910 0.79 ALOX5AP (0.36) GSK3AGSK3BALDH1A1KDM4EHPGD
SCHEMBL10073160 0.76 ALDH1A1 (0.38) GSK3AGSK3BALDH1A1KDM4EHPGD
SCHEMBL12243428 0.74 TRPA1 (0.38) GSK3AGSK3BALDH1A1KDM4EHPGD
SCHEMBL10073159 0.73 ALDH1A1 (0.35) GSK3AGSK3BALDH1A1KDM4EHPGD
SCHEMBL10073849 0.72 NR3C1 (0.36) GSK3AGSK3BALDH1A1KDM4EHPGD
SCHEMBL10073652 0.72 ALDH1A1 (0.33) GSK3AGSK3BALDH1A1FTOMAPT
SCHEMBL10073164 0.71 ALDH1A1 (0.41) ALDH1A1KDM4EHPGDMEN1KMT2A
SCHEMBL10073459 0.71 SMN1; SMN2 (0.36) ALDH1A1MEN1KMT2AHTT
SCHEMBL10072911 0.71 UTS2R (0.39) GSK3AGSK3BALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8445681-B2 Azaindazoles useful as inhibitors of kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-05-21 US disclosed
EP-2514751-A1 Azaindazoles useful as inhibitor of kinases Vertex Pharmaceuticals, Inc. (US) 2012-10-24 EP disclosed
US-20120165367-A1 AZAINDAZOLES USEFUL AS INHIBITORS OF KINASES VERTEX PHARMACEUTICALS INCORPORATED 2012-06-28 US disclosed
US-8017781-B2 Azaindazoles useful as inhibitors of kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-09-13 US disclosed
US-8017781-B2 Azaindazoles useful as inhibitors of kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-09-13 US disclosed
US-20070179177-A1 Azaindazoles useful as inhibitors of kinases VERTEX PHARMACEUTICALS INCORPORATED 2007-08-02 US disclosed
US-20070179177-A1 Azaindazoles useful as inhibitors of kinases VERTEX PHARMACEUTICALS INCORPORATED 2007-08-02 US disclosed
WO-2007059219-A1 AZAINDAZOLES USEFUL AS INHIBITORS OF KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179177-A1 Azaindazoles useful as inhibitors of kinases PRKDC, MAP3K20, PRKACA GSK3A 188/4885GSK3B 237/4885ALDH1A1 3237/4885
US-20120165367-A1 AZAINDAZOLES USEFUL AS INHIBITORS OF KINASES PRKDC, MAP3K20, PRKACA GSK3A 188/4885GSK3B 237/4885ALDH1A1 3237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.